-
The symptoms of nearly half of the express patients improved by at least 40%, and AbbVie's JAK inhibitor was approved by the FDA
Time of Update: 2022-05-28
S. FDA approved the expanded indication of its JAK inhibitor Rinvoq (upadacitinib, upadacitinib) for the treatment of active ankylosing spondylitis (ankylosing spondylitis, AS) adult patients .
-
Upstart BTK inhibitor sells at least $11 billion globally in 2021
Time of Update: 2022-05-28
Globally Approved BTK Inhibitors(Source: CITIC Securities Research)Sales of major BTK inhibitors have continued to grow since their launch .
-
Bayer withdraws PI3K inhibitor application for one indication
Time of Update: 2022-05-28
Bayer submitted the first domestic application for the product in March 2021 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two systemic therapies in the past.
-
Bayer's Kerendia gets EU approval to compete with AZ and Eli Lilly's SGLT-2 inhibitors
Time of Update: 2022-05-28
Compilenewborn>Recently, Bayer's new kidney disease drug Kerendia (finerenone, feneridone, 10mg or 20mg) was approved in the European Union, the drug
-
AbbVie Upatinib Approved in my country to Inventory 8 Iteratively Marketed JAK Inhibitors Worldwide
Time of Update: 2022-05-28
Text by Bu Yuan>On February 24, the official website of China's National Medical Products Administration (NMPA) showed that AbbVie's JAK inhibitor upadatinib
-
Interim Analysis Shows Positive Efficacy SGLT2 Inhibitor Early Termination of Phase 3 Clinical Trial
Time of Update: 2022-05-27
On March 17, Eli Lilly and Company and Boehringer Ingelheim jointly announced that the SGLT2 inhibitor empagliflozin for the treatment of chronic kidney disease (CKD) patients was based on the recommendation of an independent data monitoring committee.
-
PD-L1 inhibitor combination has been granted priority review by the FDA
Time of Update: 2022-05-27
” Reference: [1] Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial.
-
-term clinical results of Novartis CDK4/6 inhibitor are positive
Time of Update: 2022-05-27
▎WuXi AppTec Content Team Editor Today, Novartis announced that its CDK4/6 inhibitor Kisqali (ribociclib) in combination with fulvestrant as first-line therapy in postmenopausal patients with HR+/HER2- advanced
-
Double progression-free survival with PARP inhibitor as first-line maintenance therapy for ovarian cancer
Time of Update: 2022-05-26
References:[1] Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial.
-
Vertex's ion channel inhibitor receives Phase 2 clinical proof of concept
Time of Update: 2022-05-26
References:[1] Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain.
-
Junjing Bio's fourth-generation EGFR inhibitor applied for clinical application
Time of Update: 2022-05-26
At present, domestic companies developing fourth-generation EGFR inhibitors include Betta Pharmaceuticals, Zai Lab, Chia Tai Tianqing, Hongyun Bio, Qilu Pharmaceutical, and Jinan University .
-
Ann Med: Outcomes in adolescents and young adults with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Time of Update: 2022-05-25
MMR: major molecular response; DMR: deep molecular response; TKI: tyrosine kinase inhibitorIn AYA patients, peripheral blood (PB) white blood cell counts and percentage of blasts were significantly elevated at diagnosis, hemoglobin levels were lower, and spleens were larger .
-
Innovent's FGFR inhibitor approved for marketing
Time of Update: 2022-05-25
Article source: Medical Cube Info>Author: info>On April 6, the NMPA approved the marketing application of Innovent Bio-Fibroblast
-
AbbVie's JAK Inhibitor "Upatinib" Approved in China for the Third Indication
Time of Update: 2022-05-25
upadatinib extended-release tablets was approved for the treatment of active patients with poor efficacy or intolerance to one or more DMARDs. Psoriatic arthritis (PsA) in adults . >
-
Baiji Baiji, Nuocheng Jianhua, Hengrui and other pharmaceutical companies enter the tens of billions of BTK inhibitor market
Time of Update: 2022-05-24
According to relevant data analysis, the global market for BTK inhibitors is growing rapidly and is expected to reach US$11.
-
Eli Lilly's Oral JAK Inhibitor Olumiant Effective in Severe COVID-19 Patients
Time of Update: 2022-05-24
/> Led by the University of Oxford, the RECOVERY trial is the world's largest study of a COVID-19 treatment involving more than 47,000 participants in the UK . The trial has tested
-
Yifang Bio's new KRAS G12C inhibitor achieved positive results in Phase 1 clinical trials
Time of Update: 2022-05-23
Transfer from | Medicine GuanlanRecently, Yifang Bio announced the first clinical data of its oral KRAS G12C inhibitor in cancer patients .
-
Pfizer's JAK1 Inhibitor "Abraxitinib" Approved in China for Atopic Dermatitis
Time of Update: 2022-05-23
Today (April 11), the official website of the National Medical Products Administration (NMPA) of China announced that Pfizer’s oral JAK1 inhibitor abrocitinib (abrocitinib, the Chinese brand
-
A&R: Tumor necrosis factor inhibitor therapy is associated with a time-shifted delay
Time of Update: 2022-05-22
In a long-term initial cohort study, we investigated the longitudinal association between radiographic sacroiliitis progression and tumor necrosis factor inhibitor (TNFi) treatment in patients with early axSpA .
-
ARD: Use of TNF inhibitors in children with juvenile idiopathic arthritis increases psoriasis incidence
Time of Update: 2022-05-22
Researchers aimed to investigate the association between tumor necrosis factor inhibitor (TNFi) treatment and new-onset psoriasis in children with juvenile idiopathic arthritis (JIA) using data from the Childhood Arthritis and Rheumatology Research Consortium (CARRA) registry .
